Physician profile
Anne Young
NPI 1760406813
$841.24
in general payments reported to CMS, 2019-2025
12 companies · $78.07 in 2025
The $78.07 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $91.38 · 2021: $77.21 · 2022: $218 · 2023: $136 · 2024: $137 · 2025: $78.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $259.89 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $182.19 | 2023-2025 | Qelbree, Qelbree |
| Pfizer INC. | $80.25 | 2019-2022 | |
| Corium, LLC | $73.75 | 2021-2023 | Azstarys |
| Adlon Therapeutics L.P. | $50.55 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.14 | 2019-2021 | |
| Shire North American Group INC | $41.18 | 2019 | |
| Genentech USA, INC. | $33.25 | 2019-2020 | |
| Neos Therapeutics, LP | $20.71 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.50 | 2025 | Relexxii |
| Tris Pharma INC | $16.95 | 2024 | Dyanavel Xr |
| Sobi, INC | $16.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.